Literature summary for 3.4.15.1 extracted from

Besancon, J.F.; Lagarce, L.; Diquet, B.; Laine-Cessac, P.
Study of the use of a spironolactone and angiotensin-converting enzyme inhibitor combination: a population-based analysis (2008), Pharmacoepidemiol. Drug Saf., 17, 172-179.

Search for more literature for 3.4.15.1

Application

Application	Comment	Organism
medicine	the use of spironolactone and angiotensin-converting enzyme inhibitor combination, in general practice, is largely inappropriate. This could explain an increased incidence of severe hyperkalemia. A risk management plan is needed to obtain a careful selection of patients who derive benefit from therapy and to minimise the risk of hyperkalemia	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)